US20100278943A1 - Anti viral composition - Google Patents

Anti viral composition Download PDF

Info

Publication number
US20100278943A1
US20100278943A1 US12/670,398 US67039808A US2010278943A1 US 20100278943 A1 US20100278943 A1 US 20100278943A1 US 67039808 A US67039808 A US 67039808A US 2010278943 A1 US2010278943 A1 US 2010278943A1
Authority
US
United States
Prior art keywords
composition
hiv
protease
hcv
reverse transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/670,398
Other languages
English (en)
Inventor
Ravigadevi Sambanthamurthi
Kalyana Sundram
Yew Ai Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palm Oil Research and Development Board
Original Assignee
Palm Oil Research and Development Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palm Oil Research and Development Board filed Critical Palm Oil Research and Development Board
Assigned to MALAYSIAN PALM OIL BOARD reassignment MALAYSIAN PALM OIL BOARD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BASRI BIN WAHID, MOHD, SUNDRAM P. MANICKAM, KALYANA, SAMBANTHAMURTHI, RAVIGADEVI, AI TAN, YEW
Publication of US20100278943A1 publication Critical patent/US20100278943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/889Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to a composition enriched but not confined to phenolic antioxidants obtained from a botanical extract of oil palm vegetation liquor obtained from the palm oil milling process, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections.
  • HIV Human Immunodeficiency Virus
  • phenolics and flavonoids are the most abundant and ubiquitous products of secondary plant metabolism. Under normal circumstances, they are often used by plants as a defense mechanism against animal predation and the like. Additionally, recent studies have begun to examine and heighten the role of agriculture in the context of producing immunity against illnesses.
  • AIDS is widely known to be caused by the virus HIV [Human Immuno-deficiency Virus], which relates to the disruption of the immune system.
  • HIV Human Immuno-deficiency Virus
  • phenolics and antioxidants are one of the most highly utilized categories of drugs and thus have been taken into account in the possibility of treating AIDS.
  • Retroviruses are widespread in nature and can be classified according to biological property, morphology and genome size. Retroviruses are characterized by the presence of the enzyme reverse transcriptase in the virions. Reverse transcriptase is required for the unique retroviral type of multiplication. After entering the cell, the uncoated viral RNA is transcribed to double stranded DNA which is then incorporated into the DNA of the host cell as a provirus. Reverse transcriptase is required for early proviral DNA synthesis and is therefore a prime target for anti-retroviral therapy including AIDS.
  • Prior art of similar purpose includes ayurvedic compositions, wherein they comprise pre-determined amount of plant extracts and compositions which consist of a combination of well known medicinal plants or herbs, for example ginseng, Radix Astragali and the like.
  • other solutions comprise pharmaceutically active compounds, having inhibitors.
  • compositions which are related to the treatment of AIDS are as disclosed in U.S. Pat. No. 5,529,778—Ayurvedic Composition for the Prophylaxis and Treatment of AIDS, Flu, TB and Other Immuno-Deficiencies and The Process Preparing the Same (Surendra Ruhatgi et al.) which suggests a composition containing the isolates and extracts of a variety of herbs, said herbs including Phyllantus niruri, Tinosfora cordifolia, phyllantus emblica, Terminalia beleria and Terminalia cherbulia. Accordingly, the said composition stimulates the physiological functions of the body for the treatment of AIDS.
  • the essential compound of this invention is the extracts or isolates from a plurality of herbs, which is distinctive from the essential compounds of the present invention
  • coconut oils may provide the superiority function of antiviral effects.
  • the content of lauric acid which is formed into monolaurin in human or animal body may provide the ability to eliminate virus including HIV, herpes, cytomegalovirus, influenza and a variety of pathogenic bacteria.
  • palm fruit Another eminent exemplary of a plant having extremely beneficial health properties is palm fruit.
  • the oil palm contains compounds which can be considered as highly effective in the treatment of serious illnesses.
  • Recent discoveries in regards to further beneficial health properties of phenolics and antioxidants which are eminently found in oil palm include providing treatments for cancer, and for eliminating skin problems.
  • the present invention provides a new approach in using oil palm, particularly in providing a treatment of AIDS by way of a composition that promotes immunity against HIV infection.
  • primary object of the present invention to provide a composition based on a botanical extract of oil palm vegetation liquor obtained from the palm oil milling process for promoting immunity against HIV virus infection and thus for treatment of AIDS.
  • the present invention relates to an antiviral composition
  • an antiviral composition comprising antioxidants extracted from the vegetation liquor of the palm oil milling process for promoting immunity and for providing inhibition against HIV infections.
  • composition of the present invention may be provided with pharmaceutically acceptable carriers.
  • Combination therapies involving HIV protease inhibitors and HIV reverse transcriptase inhibitors are the cornerstones of currently recommended therapies for HIV infection.
  • the botanical extract of vegetation liquor from the palm oil milling process as well as its purified fractions have potent inhibitory action against both HIV protease and reverse transcriptase as well as hepatitis C (HCV) protease.
  • the present invention further relates to the use of therapeutically effective amount of a composition in the preparation of a medicament for promoting immunity and for providing inhibition against HIV and HCV infections in a patient in need thereof, wherein the composition may be administered orally or as supplements or with additives.
  • phenolics refers to a class of compounds grouped together due to their chemical structure wherein in this document is extracted from vegetation liquor of the palm oil milling process.
  • flavonoids refers to naturally occurring chemicals in plants, wherein in this document is extracted from vegetation liquor of the palm oil milling process
  • the present invention provides a composition based on but not confined to the antioxidants and phenolics obtained from vegetation liquor of the palm oil milling process promoting immunity against HIV virus infection and thus for treatment of AIDS.
  • the present invention is to provide a broad spectrum antiviral composition which comprises but is not limited to antioxidants and phenolics obtained from vegetation liquor of the palm oil milling process.
  • the composition comprising antioxidants, phenolic acids and flavonoids and the usage of the said composition in a medicament for providing immunity against and thus treatment of mixed viral infections.
  • composition formulations according to the present invention are described in detail by referring to the experimental examples. However, the present invention is not limited to these examples.
  • the method and preparation of the antiviral composition comprise the steps of isolating the main compounds.
  • the main compounds or extract of the composition of the present invention can be prepared in a variety of appropriate ways, however should not be considered as limiting the scope of invention, but merely as being illustrative.
  • the isolated extracts mainly comprise phenolic compounds, fruit acids, fruit sugars and glycerol from the vegetation liquor from the palm oil milling process and the prepared formulations containing these extracts.
  • Isolation methods include, and not limiting to, filtration, distillation, crystallization and flash column chromatography.
  • the main requirement for the isolation is highly pure and concentrated samples.
  • the preferred isolation method in accordance to the present invention is membrane filtration employing molecular weight cut-off sieves.
  • the resultant filtrate (botanical extract) is further separated using flash column chromatography.
  • the said isolation method may consist of extracting the crude oil palm product, with a predetermined yield rate.
  • the biologically active extracts of palm vegetation liquor useful in this invention can be prepared by any means capable of extracting phenolic compounds from the vegetation liquor using standard extraction techniques or techniques as described in US Patent Application No. 20030031740 (Sambanthamurthi, Tan and Sundram 2004).Such extractions include but are not limited to ethanol, methanol, acetone, ethyl acetate and butanol. In addition to direct use of an extract, it is also possible to use different fractions of the oil palm phenolic compounds. What constitutes an effective amount of an extract, or an active portion thereof, will depend on the purity of the extract
  • the preparations of extracts are preferably in the liquid and dried forms as shown in FIG. 2 of the present invention.
  • the preferred, assay system for analyzing the human immunodeficiency virus (HIV) replication activity for particle associated in accordance to the present invention is the Reverse Transcriptase system.
  • the viral activity can be determined by way of a Reverse Transcriptase Assay. Inhibition of reverse transcriptase is thus indicative of anti-viral and more specifically anti-HIV activity when HIV reverse transcriptase is used in the assay.
  • the Reverse Transcriptase Assay takes advantage of the ability of reverse transcriptase to synthesize DNA, starting from the template/primer hybrid poly (A) ⁇ oligo (dT)15. Digoxigenin- and biotin-labeled nucleotides in an optimized ratio are incorporated into one and the same DNA molecule, which is freshly synthesized by the RT.
  • the detection and quantification of synthesized DNA as a parameter for RT activity follows a sandwich ELISA protocol: Biotin-labeled DNA binds to the surface of microtiter, plate (MTP) modules that have been precoated with streptavidin.
  • MTP microtiter, plate
  • an antibody to digoxigenin, conjugated to peroxidase binds to the digoxigenin-labeled DNA.
  • the peroxidase substrate ABTS is added. The peroxidase enzyme catalyzes the cleavage of the substrate, producing a colored reaction product.
  • the absorbance of the samples can be determined using a microtiter plate (ELISA) reader and is directly correlated to the level of RT activity in the sample.
  • ELISA microtiter plate
  • a reverse transcriptase, HIV-1 recombinant was used in conjunction with the Reverse Transcriptase Assay, Colorimetric.
  • the assay was carried out according to manufacturers' instructions. (Cat. No. 1 468 120)
  • the extract was prepared at various concentrations in both the dried and aqueous form.
  • the four fractions from flash chromatography were also prepared with varying concentrations.
  • FIG. 2 of the present invention both the dried and aqueous extracts exhibited significant inhibitory action against HIV-1 reverse trancriptase.
  • the activity was dose-dependent with both the dried and aqueous extracts at 1500 ppm gallic acid equivalent exhibiting more than 90% inhibition in activity as seen by the decrease in absorbance at these concentrations.
  • Molecular Probes EnzChek® Reverse Transcriptase Assay uses Pico Green dsDNA quantitation reagent which preferentially detects dsDNA or RNA-DNA heteroduplexes over single-stranded nucleic acids or free nucleotides.
  • reverse trancriptase generates long RNA-DNA heteroduplexes from a mixture of a long poly (A) template, an oligo-dT primer and DTTP.
  • the RNA-DNA heteroduplexes formed are then detected by the PicoGreen reagent.
  • a fixed amount of reverse transcriptase is incorporated in the assay and the reduction in activity quantified. The detailed experimental protocol was carried out according to manufacturer's instructions.
  • proteases are enzymes that aid in the maturation of other viral proteins, making them functional. For example, without the work of protease, HIV will not mature properly and therefore will not be able to make copies of itself and infect other cells. This is also true for other virus such as the Hepatitis C virus (HCV).
  • HCV Hepatitis C virus
  • protease activity is indicative of anti-viral activity.
  • Protease Inhibitors are medications that block the functioning of the enzyme protease. Without functioning protease, HIV and HCV are unable to mature and therefore cannot make more copies of themselves thus lowering the viral loads carried by AIDS and HCV patents.
  • the EnzoLyteTM 620 HCV Protease Assay kit which is optimized for detecting the activity of hepatitis C virus NS3/4A protease was used to test the inhibitory effect of the extract.
  • the NS3/4A protease of hepatitis C virus (HCV) is required for the cleavage of viral nonstructural polyprotein at the NS3-NS4A, NS4A-NS4B, NS4B-NS5A sites. Three cleavage sites are essential for the maturation of the viral proteins. This protease is one of the key targets for developing anti-HCV drugs.
  • the FRET peptide was derived from the cleavage site of NS4A/NS4B.
  • the fluorescence of HiLye FluorTM was quenched by QXLTM610.
  • the SensoLyteTM 520 HIV Assay kit used a new FRET peptide substrate that incorporated HiLyte FluorTM 488 (fluorophore) and QXLTM 520 (quencher) for measurement of enzyme activities.
  • HiLyte FluorTM 488 fluorophore
  • QXLTM 520 quencher
  • the fluorescence of HiLyte FluorTM 488 was quenched by QXLTM 520.
  • the botanical extract of vegetation liquor from the palm oil milling process showed significantly higher inhibitory action against HIV protease.
  • the Molecular Probes' EnzChek Protease Assay Kit was used to further test for protease inhibitory action of oil palm extracts.
  • the kit used a fluorescence-based assay for detecting metallo-, serine and sulfydryl proteases. It contained casein derivatives which were heavily labeled with the pH-insensitive green fluorescent BODIPY FL or red-fluorescent BODIPY TR-X dyes resulting in almost total quenching of the conjugate's fluorescence.
  • Protease-catalysed hydrolysis released highly fluorescent BODIPY FL or BODIPY TR-X dye-labeled peptides. The accompanying increase in fluorescence was measured in a microplate reader. Inhibitors thus would decrease the fluorescence.
  • FIG. 5 shows the results obtained using the protease chymotrypsin and casein derivative labeled with green fluorescent BODIPY FL dye as substrate
  • the botanical extract of palm and the partially purified fractions showed significantly higher protease inhibitory action compared to even the commercial inhibitor (inhibitor) supplied with the kit.
  • the botanical extracts of vegetation liquor of the palm oil milling process as well as partially purified fractions showed potent inhibition against HIV reverse transcriptase and protease and HCV protease in vitro and hence are potentially useful for development of future antiviral therapies including hepatitis C virus (HCV) therapies.
  • HCV hepatitis C virus
  • the compounds of the present invention may be formulated in a wide variety of oral administration dosage form and carriers. It can be in the form of tablets, capsules, solutions, emulsions, syrups or suspensions. Nevertheless, composition of the present invention may be efficacious when used together with one or more additives in conventional proportions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/670,398 2007-07-23 2008-07-23 Anti viral composition Abandoned US20100278943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI20071192A MY184667A (en) 2007-07-23 2007-07-23 An antiviral composition
MYPI20071192 2007-07-23
PCT/MY2008/000075 WO2009014417A2 (en) 2007-07-23 2008-07-23 An antiviral composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2008/000075 A-371-Of-International WO2009014417A2 (en) 2007-07-23 2008-07-23 An antiviral composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/633,041 Division US10130672B2 (en) 2007-07-23 2012-10-01 Antiviral composition

Publications (1)

Publication Number Publication Date
US20100278943A1 true US20100278943A1 (en) 2010-11-04

Family

ID=40281998

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/670,398 Abandoned US20100278943A1 (en) 2007-07-23 2008-07-23 Anti viral composition
US13/633,041 Active US10130672B2 (en) 2007-07-23 2012-10-01 Antiviral composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/633,041 Active US10130672B2 (en) 2007-07-23 2012-10-01 Antiviral composition

Country Status (6)

Country Link
US (2) US20100278943A1 (zh)
EP (1) EP2182937B1 (zh)
CN (1) CN101815516B (zh)
BR (1) BRPI0814725B8 (zh)
MY (1) MY184667A (zh)
WO (1) WO2009014417A2 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320822A1 (en) * 2012-12-13 2015-11-12 Malaysian Palm Oil Board Anti-Proliferative Effects of Palm Vegetation Liquor And Extracts Thereof In Preventing Pancreatic Cancer
US10813972B2 (en) 2013-02-06 2020-10-27 Malaysian Palm Oil Board Treatment of DNA damage and mitochondrial dysfunction using palm fruit juice

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161839A (en) 2009-05-18 2017-05-15 Malaysian Palm Oil Board A composition for use in the prevention and treatment of cardiovascular diseases
MY185582A (en) 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
CN102475202A (zh) * 2010-11-29 2012-05-30 王玫 一种金牛果核驱铅保健食品、药品及其加工方法
MY185831A (en) * 2012-07-27 2021-06-11 Malaysian Palm Oil Board Bioactive compound obtained from oil palm base materials and uses thereof
MY178049A (en) * 2013-02-21 2020-09-30 Malaysian Palm Oil Board Composition with inhibitory effect on viral integrase activity
CN110055355B (zh) * 2019-05-15 2022-08-09 山东中医药大学 中药诃子和西青果抗流感活性的筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US20030031740A1 (en) * 1998-09-24 2003-02-13 Ravigadevi Sambanthamurthi Treatment of vegetation liquors derived from oil-bearing fruit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866606A (en) * 1996-07-31 1999-02-02 Abbott Laboratories Nutritional formulations containing water-miscible lipid derivatives as anti-microbial agents
US6083921A (en) * 1998-01-12 2000-07-04 Xu; Kai Jian Pharmaceutical compositions and method of using same
GB0026018D0 (en) * 2000-10-24 2000-12-13 Novartis Nutrition Ag New composition
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
KR101323513B1 (ko) * 2004-08-10 2013-10-29 엔지모테크 리미티드 의학적 증상의 치료에서의 사용을 위한 피토스테롤에스테르(들) 및 1,3-디글리세라이드(들)의 혼합물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US20030031740A1 (en) * 1998-09-24 2003-02-13 Ravigadevi Sambanthamurthi Treatment of vegetation liquors derived from oil-bearing fruit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oil Palm, Wikipedia, Online, archived to 20 April 2005, URL<http://web.archive.org/web/20050420071030/http://en.wikipedia.org/wiki/Oil_palm, Accessed 5/21/2012, 2 pages. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320822A1 (en) * 2012-12-13 2015-11-12 Malaysian Palm Oil Board Anti-Proliferative Effects of Palm Vegetation Liquor And Extracts Thereof In Preventing Pancreatic Cancer
US10342844B2 (en) 2012-12-13 2019-07-09 Malaysian Palm Oil Board Anti-proliferative effects of palm vegetation liquor and extracts thereof in preventing pancreatic cancer
US10813972B2 (en) 2013-02-06 2020-10-27 Malaysian Palm Oil Board Treatment of DNA damage and mitochondrial dysfunction using palm fruit juice

Also Published As

Publication number Publication date
EP2182937A2 (en) 2010-05-12
BRPI0814725B1 (pt) 2021-05-11
BRPI0814725B8 (pt) 2021-05-25
EP2182937B1 (en) 2016-08-31
US20130131158A1 (en) 2013-05-23
MY184667A (en) 2021-04-15
CN101815516A (zh) 2010-08-25
WO2009014417A2 (en) 2009-01-29
US10130672B2 (en) 2018-11-20
BRPI0814725A2 (pt) 2015-08-04
EP2182937A4 (en) 2013-01-23
CN101815516B (zh) 2012-12-26
WO2009014417A3 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
US10130672B2 (en) Antiviral composition
Montenegro-Landívar et al. Polyphenols and their potential role to fight viral diseases: An overview
CN113244211B (zh) 黄芩素、黄芩苷用于制备冠状病毒SARS-CoV-2的3CL蛋白酶的抑制剂的用途
CN113209164B (zh) 黄芩、连翘、金银花主要成分及其组合物在抗冠状病毒中的应用
JPH02111725A (ja) 医薬組成物
CN113491703A (zh) 苯乙醇苷类化合物及其组合物在制备防治新冠肺炎药物中的应用
CN113350330B (zh) 杨梅素类化合物在制备防治新冠肺炎药物中的应用
EP4154878A1 (en) Application of active ingredient of root of ligulilobe sage or pharmaceutically acceptable salt thereof in preparing antiviral drug
CN113855654B (zh) 一种预防和治疗冠状病毒感染的组合物
CN113332363A (zh) 茶叶提取物及其组合物在抗冠状病毒中的应用
CN113648337B (zh) 雷公藤红素在制备抑制马立克氏病病毒复制的药物中的应用
CN106038695B (zh) 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途,以及包含鳄梨萃取物的保健食品
CN114452271B (zh) 一种二芳基丁烷类化合物在制备抑制新冠病毒的药物中的应用
KR20090125879A (ko) 항hiv제 조성물
EP4223303A1 (en) Antiviral agent for preventing or treating covid-19 infection
CN111265539B (zh) 银椴苷在制备抗流感药物中的应用
TW202139995A (zh) 魚針草內酯抗新型冠狀病毒之用途
CN113893345A (zh) 247种化合物及其组合物在抗新型冠状病毒感染中的应用
WO2023065223A1 (zh) 鱼针草酸在制备抑制新型冠状病毒与变异株的感染与复制的医药组合物中的用途
CN115867301A (zh) 草药组合物、其制备方法及将其施用以用于预防或治疗病毒感染的方法
Moghaddam et al. Sera of Rats Fed With Baicalein Showed Effective Against Dengue Virus Replication
CN113288935A (zh) 含黄芩的中药复方制剂在抗冠状病毒中的应用
CN118403050A (zh) 异欧前胡素及其类似物在制备预防和/或治疗冠状病毒所致疾病的药物中的应用
AU2014207946A1 (en) An antiviral pharmaceutical composition
KR100386310B1 (ko) 천연물로부터 분리한 항 hiv 제제

Legal Events

Date Code Title Description
AS Assignment

Owner name: MALAYSIAN PALM OIL BOARD, MALAYSIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAMBANTHAMURTHI, RAVIGADEVI;SUNDRAM P. MANICKAM, KALYANA;AI TAN, YEW;AND OTHERS;SIGNING DATES FROM 20100503 TO 20100511;REEL/FRAME:024577/0494

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION